Literature DB >> 120384

Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas.

J E Pennington, R M Stone.   

Abstract

The high mortality associated with pneumonia due to Pseudomonas aeruginosa prompted a comparative trial of several currently available antibiotic regimens for this infection in a guinea pig model. Normal guinea pigs receiving an intratracheal challenge of 10(8) colony-forming units of Pseudomonas routinely died within 3-48 hr when treated with saline injections. Treatment with carbenicillin or ticarcillin did not affect this uniformly fatal outcome. Groups of animals treated with gentamicin or tobramycin had survival rates of 39% and 67%, respectively. The addition of either carbenicillin or ticarcillin to an aminoglycoside failed to enhance further the survival rates or durations of survival after infection. These survival data were supported by studies showing superior clearance of viable Pseudomonas from lung tissues in aminoglycoside-treated animals chosen at random for sacrifice 3 hr after infection. Thus, in animals experimentally challenged with P. aeruginosa to cause pneumonia and in which only a single isolate of Pseudomonas was evaluated, protection from pulmonary infection was best provided by an aminoglycoside rather than by a beta-lactam antibiotic.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 120384     DOI: 10.1093/infdis/140.6.881

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Direct examination and cultures of bronchoalveolar lavage in pneumonia diagnosis: a comparative experimental study.

Authors:  Nilton Brandão da Silva; Lucas Martins; Frederico Martins; José Anflor; Tiago Tonietto; Cristiano Koefender; Paulo G Cardoso; José Moreira
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

3.  Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test.

Authors:  I Braveny; K Machka; D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa.

Authors:  R H Eng; S M Smith; C Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; C E Johnson
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

9.  Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model.

Authors:  A U Gerber; S Kozak; C Segessenmann; U Flückiger; T Bangerter; U Greter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

10.  Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs.

Authors:  L L Blackwood; J E Pennington
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.